^
No biomarker
Malignant Pleural Mesothelioma
nivolumab + ipilimumab
Sensitive
:
A1
Bristol-Myers Squibb Press Release - 2wk
No biomarker
Malignant Pleural Mesothelioma
pemetrexed
Sensitive
:
A1
No biomarker
Malignant Pleural Mesothelioma
carboplatin + pemetrexed
Sensitive
:
A2
No biomarker
Malignant Pleural Mesothelioma
nivolumab
Sensitive
:
A2
No biomarker
Malignant Pleural Mesothelioma
bevacizumab
Sensitive
:
A2
No biomarker
Malignant Pleural Mesothelioma
pembrolizumab
Sensitive
:
A2
No biomarker
Malignant Pleural Mesothelioma
cisplatin + pemetrexed
Sensitive
:
A2
No biomarker
Mesothelioma
GC
Sensitive
:
A2
No biomarker
Mesothelioma
bevacizumab
Sensitive
:
A2
No biomarker
Mesothelioma
cisplatin + raltitrexed
Sensitive
:
A2
No biomarker
Mesothelioma
nivolumab
Sensitive
:
A2
No biomarker
Malignant Pleural Mesothelioma
carboplatin + raltitrexed
Sensitive
:
A2
No biomarker
Malignant Pleural Mesothelioma
GC
Sensitive
:
A2
No biomarker
Malignant Pleural Mesothelioma
gemcitabine
Sensitive
:
A2
No biomarker
Malignant Pleural Mesothelioma
vinorelbine tartrate
Sensitive
:
A2
BRCA1 mutation
Mesothelioma
rucaparib
Sensitive
:
C1
BAP1 mutation
Mesothelioma
tazemetostat
Sensitive
:
C2
PD-L1 expression
Malignant Pleural Mesothelioma
nivolumab
Sensitive
:
C3
WT1 expression
Malignant Pleural Mesothelioma
nivolumab + galinpepimut-S
Sensitive
:
C3
TMB-L
Malignant Pleural Mesothelioma
PD1 inhibitor
Resistant
:
C3
TMB-L
Malignant Pleural Mesothelioma
PD-L1 inhibitor
Resistant
:
C3
PD-L1 underexpression
Malignant Pleural Mesothelioma
PD1 inhibitor
Resistant
:
C3
BAP1 negative + BRCA1 mutation
Mesothelioma
rucaparib
Sensitive
:
C3
BAP1 negative
Mesothelioma
rucaparib
Sensitive
:
C3
MRE11A mutation
Mesothelioma
olaparib
Sensitive
:
C3
VERI is free for non-commercial use, no login needed.
Content on this site is for research purposes only and is not intended  to be a substitute for medical advice.
For commercial access, including additional premium features, please contact us.
By using VERI, you are agreeing to our